Work

Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) Treatment on Clinical Outcomes in a Single Centre Cohort of Paediatric Patients With Cystic Fibrosis

Year: 2025

Type: article

Abstract: Cystic Fibrosis (CF) affects approximately 3800 Australians, including 42% aged under 18 years [1].CF is associated with significant morbidity, with many people spending at least 60 min per day on treatment.Life expectancy has progressively improved due to the development of new therapies: median survival is now 60.6 years, increased from 47 years in 2008 [1].Elexacaftor, Tezacaftor and Ivacaftor (ETI) (Trikafta), the first triple-therapy CF transmembrane conductance regulator modulator, became available in Australia on the Pharmaceutical Benefits Scheme in 2022.This study aimed to measure changes in the clinical status of adolescents with CF who have completed 12-months of treatment with ETI in a real-world setting.

Source: Journal of Paediatrics and Child Health

DOI: 10.1111/jpc.70249

Authors: Chloe Crainie, K. Frayman, J. Harrison

Institutions: The University of Melbourne, University of Aberdeen, Royal Children's Hospital, Murdoch Children's Research Institute

Language: English

Topic: Cystic Fibrosis Research Advances

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Cystic Fibrosis in Australia